They are also in some cases acquiring manufacturing sites from biopharmaceutical firms as a way to rapidly increase capacity.
Large biopharmaceutical companies are acquiring CMOs to ensure access to capacity, particularly in emerging markets, where it is difficult to gain entry for international companies.